ID   UBP2_HUMAN              Reviewed;         605 AA.
AC   O75604; B0YJB8; E9PPM2; Q8IUM2; Q8IW04; Q96MB9; Q9BQ21;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   27-MAR-2002, sequence version 2.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 2;
DE            EC=3.4.19.12;
DE   AltName: Full=41 kDa ubiquitin-specific protease;
DE   AltName: Full=Deubiquitinating enzyme 2;
DE   AltName: Full=Ubiquitin thioesterase 2;
DE   AltName: Full=Ubiquitin-specific-processing protease 2;
GN   Name=USP2; Synonyms=UBP41;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RA   Gong L., Yeh E.T.H.;
RT   "Cloning and expression of the human and mouse UBP41.";
RL   Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Prostate cancer;
RA   Rossi S., Graner E., Weinstein L.J., Loda M.;
RT   "Molecular cloning and characterization of USP2b in the human prostate
RT   cancer cell line LNCaP.";
RL   Submitted (OCT-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (FEB-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lymph, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, INTERACTION WITH MDM2, AND MUTAGENESIS OF HIS-549.
RX   PubMed=17290220; DOI=10.1038/sj.emboj.7601567;
RA   Stevenson L.F., Sparks A., Allende-Vega N., Xirodimas D.P., Lane D.P.,
RA   Saville M.K.;
RT   "The deubiquitinating enzyme USP2a regulates the p53 pathway by
RT   targeting Mdm2.";
RL   EMBO J. 26:976-986(2007).
RN   [9]
RP   FUNCTION, INTERACTION WITH CCND1, AND MUTAGENESIS OF CYS-276.
RX   PubMed=19917254; DOI=10.1016/j.molcel.2009.10.018;
RA   Shan J., Zhao W., Gu W.;
RT   "Suppression of cancer cell growth by promoting cyclin D1
RT   degradation.";
RL   Mol. Cell 36:469-476(2009).
RN   [10]
RP   FUNCTION, INTERACTION WITH MDM2 AND MDM4, INDUCTION, AND MUTAGENESIS
RP   OF HIS-549.
RX   PubMed=19838211; DOI=10.1038/onc.2009.330;
RA   Allende-Vega N., Sparks A., Lane D.P., Saville M.K.;
RT   "MdmX is a substrate for the deubiquitinating enzyme USP2a.";
RL   Oncogene 29:432-441(2010).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=20403044; DOI=10.1111/j.1440-1827.2010.02496.x;
RA   Wang S., Wu H., Liu Y., Sun J., Zhao Z., Chen Q., Guo M., Ma D.,
RA   Zhang Z.;
RT   "Expression of USP2-69 in mesangial cells in vivo and in vitro.";
RL   Pathol. Int. 60:184-192(2010).
RN   [12]
RP   INTERACTION WITH KCNQ1.
RX   PubMed=22024150; DOI=10.1016/j.hrthm.2011.10.026;
RA   Krzystanek K., Rasmussen H.B., Grunnet M., Staub O., Olesen S.P.,
RA   Abriel H., Jespersen T.;
RT   "Deubiquitylating enzyme USP2 counteracts Nedd4-2-mediated
RT   downregulation of KCNQ1 potassium channels.";
RL   Heart Rhythm 9:440-448(2012).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 251-605.
RG   Structural genomics consortium (SGC);
RT   "Covalent ubiquitin-usp2 complex.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 258-605 IN COMPLEX WITH
RP   UBIQUITIN AND ZINC-BINDING, AND ENZYME REGULATION.
RX   PubMed=16905103; DOI=10.1016/j.str.2006.06.012;
RA   Renatus M., Parrado S.G., D'Arcy A., Eidhoff U., Gerhartz B.,
RA   Hassiepen U., Pierrat B., Riedl R., Vinzenz D., Worpenberg S.,
RA   Kroemer M.;
RT   "Structural basis of ubiquitin recognition by the deubiquitinating
RT   protease USP2.";
RL   Structure 14:1293-1302(2006).
CC   -!- FUNCTION: Hydrolase that deubiquitinates polyubiquitinated target
CC       proteins such as MDM2, MDM4 and CCND1. Isoform 1 and isoform 4
CC       possess both ubiquitin-specific peptidase and isopeptidase
CC       activities. Deubiquitinates MDM2 without reversing MDM2-mediated
CC       p53/TP53 ubiquitination and thus indirectly promotes p53/TP53
CC       degradation and limits p53 activity. Has no deubiquitinase
CC       activity against p53/TP53. Prevents MDM2-mediated degradation of
CC       MDM4. Plays a role in the G1/S cell-cycle progression in normal
CC       and cancer cells. Plays a role in the regulation of myogenic
CC       differentiation of embryonic muscle cells. Regulates the circadian
CC       clock by modulating its intrinsic circadian rhythm and its
CC       capacity to respond to external cues. Associates with clock
CC       proteins and deubiquitinates core clock component PER1 but does
CC       not affect its overall stability. Regulates the nucleocytoplasmic
CC       shuttling and nuclear retention of PER1 and its repressive role on
CC       the clock transcription factors CLOCK and ARNTL/BMAL1 (By
CC       similarity). {ECO:0000250|UniProtKB:O88623,
CC       ECO:0000269|PubMed:17290220, ECO:0000269|PubMed:19838211,
CC       ECO:0000269|PubMed:19917254}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC   -!- ENZYME REGULATION: Cleavage is inhibited by ubiquitin in a dosage-
CC       dependent manner. Cleavage is blocked by ubiquitin aldehyde.
CC       {ECO:0000269|PubMed:16905103}.
CC   -!- SUBUNIT: Homooligomer (By similarity). Found in trimeric complex
CC       with MDM2 and MDM4 and USP2. Interacts with CCND1; the interaction
CC       is direct and promotes its stabilization by antagonizing
CC       ubiquitin-dependent degradation. Interacts (via N-terminus and C-
CC       terminus) with MDM2. Interacts with MDM4. Interacts with PER1 (By
CC       similarity). Interacts with KCNQ1; counteracts the NEDD4L-specific
CC       down-regulation of I(Ks) and restore plasma membrane localization
CC       of KCNQ1 (PubMed:22024150). {ECO:0000250|UniProtKB:O88623,
CC       ECO:0000250|UniProtKB:Q5U349, ECO:0000269|PubMed:17290220,
CC       ECO:0000269|PubMed:19838211, ECO:0000269|PubMed:19917254,
CC       ECO:0000269|PubMed:22024150}.
CC   -!- INTERACTION:
CC       Q96JN2-2:CCDC136; NbExp=3; IntAct=EBI-743272, EBI-10171416;
CC       Q8IYA8:CCDC36; NbExp=3; IntAct=EBI-743272, EBI-8638439;
CC       Q2TAC2:CCDC57; NbExp=3; IntAct=EBI-743272, EBI-2808286;
CC       Q08379:GOLGA2; NbExp=3; IntAct=EBI-743272, EBI-618309;
CC       B2RA10:HOMER3; NbExp=3; IntAct=EBI-743272, EBI-10175777;
CC       Q9UJC3:HOOK1; NbExp=3; IntAct=EBI-743272, EBI-746704;
CC       Q9BVG8:KIFC3; NbExp=3; IntAct=EBI-743272, EBI-2125614;
CC       P19012:KRT15; NbExp=5; IntAct=EBI-743272, EBI-739566;
CC       Q6A162:KRT40; NbExp=5; IntAct=EBI-743272, EBI-10171697;
CC       Q969G2:LHX4; NbExp=3; IntAct=EBI-743272, EBI-2865388;
CC       Q9BRK4:LZTS2; NbExp=5; IntAct=EBI-743272, EBI-741037;
CC       Q00987:MDM2; NbExp=4; IntAct=EBI-743272, EBI-389668;
CC       Q5JR59:MTUS2; NbExp=3; IntAct=EBI-743272, EBI-742948;
CC       Q9GZM8:NDEL1; NbExp=5; IntAct=EBI-743272, EBI-928842;
CC       I6L9F6:NEFL; NbExp=3; IntAct=EBI-743272, EBI-10178578;
CC       Q8ND90:PNMA1; NbExp=3; IntAct=EBI-743272, EBI-302345;
CC       Q12933:TRAF2; NbExp=6; IntAct=EBI-743272, EBI-355744;
CC       Q9Y4K3:TRAF6; NbExp=3; IntAct=EBI-743272, EBI-359276;
CC       P14373:TRIM27; NbExp=5; IntAct=EBI-743272, EBI-719493;
CC       Q8N1B4:VPS52; NbExp=5; IntAct=EBI-743272, EBI-2799833;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:O88623}.
CC       Cytoplasm, perinuclear region {ECO:0000250|UniProtKB:O88623}.
CC       Note=Localizes in the spermatid head in late-elongating spermatids
CC       in the thin area between the outer acrosomal membrane and the
CC       plasma membrane. {ECO:0000250|UniProtKB:Q5U349}.
CC   -!- SUBCELLULAR LOCATION: Isoform 4: Nucleus
CC       {ECO:0000250|UniProtKB:Q5U349}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=USP2a, USP2-69;
CC         IsoId=O75604-1; Sequence=Displayed;
CC       Name=2; Synonyms=USP2b;
CC         IsoId=O75604-2; Sequence=VSP_005256, VSP_005257;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=O75604-3; Sequence=VSP_039559;
CC         Note=Ref.7 (AAH41366) sequence is in conflict in position:
CC         10:Y->S. {ECO:0000305};
CC       Name=4;
CC         IsoId=O75604-4; Sequence=VSP_039560;
CC   -!- TISSUE SPECIFICITY: Expressed in mesangial cells of the kidney and
CC       in different types of glomerulonephritides (at protein level).
CC       {ECO:0000269|PubMed:20403044}.
CC   -!- INDUCTION: Down-regulated by cisplatin (at protein level).
CC       {ECO:0000269|PubMed:19838211}.
CC   -!- DOMAIN: The different N-terminus extensions of isoform 1 and
CC       isoform 4 determine their respective subcellular localization and
CC       differentiel effect on myoblast fusion and accumulation of muscle-
CC       specific proteins. The different N-terminus extensions of isoform
CC       1 and isoform 4 are not essential for their catalytic activity.
CC       {ECO:0000250|UniProtKB:Q5U349}.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. USP2 subfamily.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF079564; AAC28392.1; -; mRNA.
DR   EMBL; AF440755; AAN65363.1; -; mRNA.
DR   EMBL; AK057225; BAB71388.1; -; mRNA.
DR   EMBL; AK292255; BAF84944.1; -; mRNA.
DR   EMBL; EF445044; ACA06096.1; -; Genomic_DNA.
DR   EMBL; EF445044; ACA06097.1; -; Genomic_DNA.
DR   EMBL; AP003396; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67484.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67485.1; -; Genomic_DNA.
DR   EMBL; CH471065; EAW67486.1; -; Genomic_DNA.
DR   EMBL; BC002854; AAH02854.1; -; mRNA.
DR   EMBL; BC002955; AAH02955.1; -; mRNA.
DR   EMBL; BC041366; AAH41366.1; -; mRNA.
DR   CCDS; CCDS58189.1; -. [O75604-3]
DR   CCDS; CCDS8422.1; -. [O75604-1]
DR   CCDS; CCDS8423.1; -. [O75604-4]
DR   RefSeq; NP_001230688.1; NM_001243759.1. [O75604-3]
DR   RefSeq; NP_004196.4; NM_004205.4. [O75604-1]
DR   RefSeq; NP_741994.1; NM_171997.2. [O75604-4]
DR   RefSeq; XP_005271778.1; XM_005271721.4. [O75604-1]
DR   RefSeq; XP_005271779.1; XM_005271722.2. [O75604-1]
DR   UniGene; Hs.524085; -.
DR   PDB; 2HD5; X-ray; 1.85 A; A=258-605.
DR   PDB; 2IBI; X-ray; 2.20 A; A=251-605.
DR   PDB; 3NHE; X-ray; 1.26 A; A=258-605.
DR   PDB; 3V6C; X-ray; 1.70 A; A=258-605.
DR   PDB; 3V6E; X-ray; 2.10 A; A=258-605.
DR   PDBsum; 2HD5; -.
DR   PDBsum; 2IBI; -.
DR   PDBsum; 3NHE; -.
DR   PDBsum; 3V6C; -.
DR   PDBsum; 3V6E; -.
DR   ProteinModelPortal; O75604; -.
DR   SMR; O75604; -.
DR   BioGrid; 114553; 101.
DR   DIP; DIP-29134N; -.
DR   IntAct; O75604; 105.
DR   MINT; MINT-4304073; -.
DR   STRING; 9606.ENSP00000260187; -.
DR   BindingDB; O75604; -.
DR   ChEMBL; CHEMBL1293227; -.
DR   MEROPS; C19.013; -.
DR   iPTMnet; O75604; -.
DR   PhosphoSitePlus; O75604; -.
DR   BioMuta; USP2; -.
DR   MaxQB; O75604; -.
DR   PaxDb; O75604; -.
DR   PeptideAtlas; O75604; -.
DR   PRIDE; O75604; -.
DR   DNASU; 9099; -.
DR   Ensembl; ENST00000260187; ENSP00000260187; ENSG00000036672. [O75604-1]
DR   Ensembl; ENST00000455332; ENSP00000407842; ENSG00000036672. [O75604-3]
DR   Ensembl; ENST00000525735; ENSP00000436952; ENSG00000036672. [O75604-4]
DR   GeneID; 9099; -.
DR   KEGG; hsa:9099; -.
DR   UCSC; uc001pwl.5; human. [O75604-1]
DR   CTD; 9099; -.
DR   DisGeNET; 9099; -.
DR   GeneCards; USP2; -.
DR   HGNC; HGNC:12618; USP2.
DR   HPA; HPA006777; -.
DR   HPA; HPA007222; -.
DR   MIM; 604725; gene.
DR   neXtProt; NX_O75604; -.
DR   OpenTargets; ENSG00000036672; -.
DR   PharmGKB; PA37244; -.
DR   eggNOG; KOG1868; Eukaryota.
DR   eggNOG; ENOG410XP8T; LUCA.
DR   GeneTree; ENSGT00860000133682; -.
DR   HOGENOM; HOG000231498; -.
DR   HOVERGEN; HBG011164; -.
DR   InParanoid; O75604; -.
DR   KO; K11833; -.
DR   OMA; MRTSYTV; -.
DR   OrthoDB; EOG091G0120; -.
DR   PhylomeDB; O75604; -.
DR   TreeFam; TF106277; -.
DR   Reactome; R-HSA-5357786; TNFR1-induced proapoptotic signaling.
DR   Reactome; R-HSA-5357905; Regulation of TNFR1 signaling.
DR   Reactome; R-HSA-5357956; TNFR1-induced NFkappaB signaling pathway.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   ChiTaRS; USP2; human.
DR   EvolutionaryTrace; O75604; -.
DR   GeneWiki; USP2; -.
DR   GenomeRNAi; 9099; -.
DR   PRO; PR:O75604; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000036672; -.
DR   CleanEx; HS_USP2; -.
DR   ExpressionAtlas; O75604; baseline and differential.
DR   Genevisible; O75604; HS.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0005813; C:centrosome; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0030332; F:cyclin binding; IPI:UniProtKB.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:FlyBase.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; TAS:Reactome.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0048512; P:circadian behavior; ISS:UniProtKB.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0043153; P:entrainment of circadian clock by photoperiod; ISS:UniProtKB.
DR   GO; GO:0045475; P:locomotor rhythm; ISS:UniProtKB.
DR   GO; GO:0007517; P:muscle organ development; IEA:UniProtKB-KW.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IDA:UniProtKB.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   Pfam; PF00443; UCH; 1.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms; Cell cycle;
KW   Complete proteome; Cytoplasm; Hydrolase; Metal-binding; Myogenesis;
KW   Nucleus; Polymorphism; Protease; Reference proteome; Thiol protease;
KW   Ubl conjugation pathway; Zinc.
FT   CHAIN         1    605       Ubiquitin carboxyl-terminal hydrolase 2.
FT                                /FTId=PRO_0000080616.
FT   DOMAIN      267    599       USP.
FT   REGION        1    200       Necessary for interaction with MDM4.
FT                                {ECO:0000269|PubMed:19838211}.
FT   REGION      403    503       Necessary for interaction with MDM4.
FT                                {ECO:0000269|PubMed:19838211}.
FT   ACT_SITE    276    276       Nucleophile. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   ACT_SITE    557    557       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   METAL       425    425       Zinc. {ECO:0000269|PubMed:16905103}.
FT   METAL       428    428       Zinc. {ECO:0000269|PubMed:16905103}.
FT   METAL       476    476       Zinc. {ECO:0000269|PubMed:16905103}.
FT   METAL       479    479       Zinc. {ECO:0000269|PubMed:16905103}.
FT   VAR_SEQ       1    258       MSQLSSTLKRYTESARYTDAHYAKSGYGAYTPSSYGANLAA
FT                                SLLEKEKLGFKPVPTSSFLTRPRTYGPSSLLDYDRGRPLLR
FT                                PDITGGGKRAESQTRGTERPLGSGLSGGSGFPYGVTNNCLS
FT                                YLPINAYDQGVTLTQKLDSQSDLARDFSSLRTSDSYRIDPR
FT                                NLGRSPMLARTRKELCTLQGLYQTASCPEYLVDYLENYGRK
FT                                GSASQVPSQAPPSRVPEIISPTYRPIGRYTLWETGKGQAPG
FT                                PSRSSSPGRDGM -> MLVPGSTRPYSKKRQ (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_039559.
FT   VAR_SEQ       1    258       MSQLSSTLKRYTESARYTDAHYAKSGYGAYTPSSYGANLAA
FT                                SLLEKEKLGFKPVPTSSFLTRPRTYGPSSLLDYDRGRPLLR
FT                                PDITGGGKRAESQTRGTERPLGSGLSGGSGFPYGVTNNCLS
FT                                YLPINAYDQGVTLTQKLDSQSDLARDFSSLRTSDSYRIDPR
FT                                NLGRSPMLARTRKELCTLQGLYQTASCPEYLVDYLENYGRK
FT                                GSASQVPSQAPPSRVPEIISPTYRPIGRYTLWETGKGQAPG
FT                                PSRSSSPGRDGM -> MRTSYTVTLPEDPPAAPFPALAKEL
FT                                RPRSPLSPSLLLSTFVGLLLNKAK (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_039560.
FT   VAR_SEQ       1    252       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.1}.
FT                                /FTId=VSP_005256.
FT   VAR_SEQ     253    258       PGRDGM -> MLNKAK (in isoform 2).
FT                                {ECO:0000303|Ref.1}.
FT                                /FTId=VSP_005257.
FT   VARIANT     174    174       R -> Q (in dbSNP:rs33929148).
FT                                /FTId=VAR_051519.
FT   VARIANT     383    383       N -> S (in dbSNP:rs45533837).
FT                                /FTId=VAR_051520.
FT   MUTAGEN     276    276       C->A: Loss of enzymatic activity.
FT                                Increases the steady-state level of
FT                                CCND1. {ECO:0000269|PubMed:19917254}.
FT   MUTAGEN     549    549       H->A: Loss of enzymatic activity.
FT                                Increases the steady-state level of MDM2
FT                                and MDM4 that leads to attenuation of
FT                                MDM2-mediated degradation of p53/TP53 and
FT                                MDM4. Increases the level of p53/TP53 and
FT                                MDM4 ubiquitin conjugates.
FT                                {ECO:0000269|PubMed:17290220,
FT                                ECO:0000269|PubMed:19838211}.
FT   CONFLICT    421    421       S -> G (in Ref. 3; BAB71388).
FT                                {ECO:0000305}.
FT   CONFLICT    501    501       H -> R (in Ref. 3; BAB71388).
FT                                {ECO:0000305}.
FT   CONFLICT    594    594       L -> H (in Ref. 1; AAC28392).
FT                                {ECO:0000305}.
FT   CONFLICT    602    605       PSRM -> TSPI (in Ref. 1; AAC28392).
FT                                {ECO:0000305}.
FT   STRAND      272    274       {ECO:0000244|PDB:3V6E}.
FT   HELIX       276    286       {ECO:0000244|PDB:3NHE}.
FT   HELIX       289    296       {ECO:0000244|PDB:3NHE}.
FT   HELIX       299    302       {ECO:0000244|PDB:3NHE}.
FT   HELIX       312    325       {ECO:0000244|PDB:3NHE}.
FT   HELIX       337    346       {ECO:0000244|PDB:3NHE}.
FT   HELIX       348    350       {ECO:0000244|PDB:3NHE}.
FT   STRAND      351    353       {ECO:0000244|PDB:3NHE}.
FT   HELIX       358    373       {ECO:0000244|PDB:3NHE}.
FT   HELIX       392    404       {ECO:0000244|PDB:3NHE}.
FT   HELIX       410    415       {ECO:0000244|PDB:3NHE}.
FT   STRAND      417    425       {ECO:0000244|PDB:3NHE}.
FT   TURN        426    428       {ECO:0000244|PDB:3NHE}.
FT   STRAND      431    443       {ECO:0000244|PDB:3NHE}.
FT   HELIX       455    463       {ECO:0000244|PDB:3NHE}.
FT   STRAND      466    468       {ECO:0000244|PDB:3NHE}.
FT   HELIX       470    472       {ECO:0000244|PDB:3NHE}.
FT   TURN        477    480       {ECO:0000244|PDB:3NHE}.
FT   STRAND      485    493       {ECO:0000244|PDB:3NHE}.
FT   STRAND      496    502       {ECO:0000244|PDB:3NHE}.
FT   HELIX       529    531       {ECO:0000244|PDB:3NHE}.
FT   STRAND      532    536       {ECO:0000244|PDB:2HD5}.
FT   STRAND      540    551       {ECO:0000244|PDB:3NHE}.
FT   STRAND      553    555       {ECO:0000244|PDB:3V6C}.
FT   STRAND      556    563       {ECO:0000244|PDB:3NHE}.
FT   TURN        565    567       {ECO:0000244|PDB:3NHE}.
FT   STRAND      570    574       {ECO:0000244|PDB:3NHE}.
FT   STRAND      577    581       {ECO:0000244|PDB:3NHE}.
FT   HELIX       583    585       {ECO:0000244|PDB:3NHE}.
FT   STRAND      591    598       {ECO:0000244|PDB:3NHE}.
SQ   SEQUENCE   605 AA;  68072 MW;  AFF4DA9344D21812 CRC64;
     MSQLSSTLKR YTESARYTDA HYAKSGYGAY TPSSYGANLA ASLLEKEKLG FKPVPTSSFL
     TRPRTYGPSS LLDYDRGRPL LRPDITGGGK RAESQTRGTE RPLGSGLSGG SGFPYGVTNN
     CLSYLPINAY DQGVTLTQKL DSQSDLARDF SSLRTSDSYR IDPRNLGRSP MLARTRKELC
     TLQGLYQTAS CPEYLVDYLE NYGRKGSASQ VPSQAPPSRV PEIISPTYRP IGRYTLWETG
     KGQAPGPSRS SSPGRDGMNS KSAQGLAGLR NLGNTCFMNS ILQCLSNTRE LRDYCLQRLY
     MRDLHHGSNA HTALVEEFAK LIQTIWTSSP NDVVSPSEFK TQIQRYAPRF VGYNQQDAQE
     FLRFLLDGLH NEVNRVTLRP KSNPENLDHL PDDEKGRQMW RKYLEREDSR IGDLFVGQLK
     SSLTCTDCGY CSTVFDPFWD LSLPIAKRGY PEVTLMDCMR LFTKEDVLDG DEKPTCCRCR
     GRKRCIKKFS IQRFPKILVL HLKRFSESRI RTSKLTTFVN FPLRDLDLRE FASENTNHAV
     YNLYAVSNHS GTTMGGHYTA YCRSPGTGEW HTFNDSSVTP MSSSQVRTSD AYLLFYELAS
     PPSRM
//
